| Total (N = 292) | RF (N = 147) | CB (N = 145) | |||
---|---|---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
Group: CB | 1.02(0.45–2.32) | 0.96 | N/A | N/A | N/A | N/A |
Age | 1.02 (0.96–1.08) | 0.50 | 1.05 (0.95–1.17) | 0.31 | 1.00 (0.95–1.07) | 0.90 |
Gender: male | 3.42 (1.09–10.71) | 0.04 | 9.77 (1.36–70.08) | 0.02 | 2.12 (0.70–6.42) | 0.19 |
CAD | 1.32 (0.25–6.96) | 0.74 | 1.93 (0.12–30.67) | 0.64 | 1.18 (0.17–8.06) | 0.87 |
Hypertension | 0.53 (0.19–1.51) | 0.24 | 0.11 (0.01–1.33) | 0.08 | 0.85 (0.30–2.40) | 0.76 |
Diabetes | 0.72 (0.22–2.43) | 0.60 | 0.63 (0.08–4.86) | 0.66 | 0.94 (0.20–4.50) | 0.94 |
Vascular disease | 0.57 (0.07–4.37) | 0.59 | 0.47 (0.02–14.38) | 0.66 | 0.30 (0.01–6.06) | 0.43 |
Common ostium | 1.36 (0.42–4.40) | 0.60 | 2.26 (0.31–16.57) | 0.42 | 1.11 (0.25–4.98) | 0.89 |
Bridging | 0.92 (0.32–2.65) | 0.88 | 0.74 (0.15–3.72) | 0.72 | 1.57 (0.31–8.08) | 0.59 |
Platelet inhibitor | 0.81 (0.20–3.31) | 0.77 | 0.52 (0.08–3.57) | 0.51 | 1.08 (0.14–8.01) | 0.94 |
DOAC vs. Phenprocoumon | 3.91 (0.30–50.12) | 0.29 | 3.14 (0.24–40.93) | 0.28 | 1.21 (0.31–4.66) | 0.78 |
Follow-up time | 0.92 (0.75–1.13) | 0.44 | 1.01 (0.82–1.24) | 0.94 | 0.90 (0.67–1.20) | 0.47 |
NavX navigation system | N/A | N/A | 0.37 (0.06–2.12) | 0.27 | N/A | N/A |
Balloon size: 23 mm | N/A | N/A | N/A | N/A | 1.89 (0.44–8.07) | 0.39 |
Balloon size: both | N/A | N/A | N/A | N/A | 0.65 (0.03–12.44) | 0.78 |
Second generation balloon | N/A | N/A | N/A | N/A | 9.77 (0.30–320.56) | 0.20 |
Achieve catheter | N/A | N/A | N/A | N/A | 1.24 (0.38–4.10) | 0.72 |
Multiple balloons | N/A | N/A | N/A | N/A | 1.26 (0.10–16.20) | 0.86 |